IVRI is proud to feature “Fab” article from UC Berkeley Pr. Jay Groves. Understanding how T Cell receptors (TCRs) are activated is fundamental in the cancer immunotherapy field. The present study is probably the first to put a quantitative measure on specific potency of a synthetic TCR ligand, and identifies the specific H57-Fab’ epitope as a potent target; both of these insights being essential in drug development.